Related Experiment Videos
Methotrexate in rheumatoid arthritis. An update
B Bannwarth1, L Labat, Y Moride
1Department of Clinical Pharmacology, Groupe Hospitalier Pellegrin, Bordeaux, France.
Drugs
|January 1, 1994
Summary
Methotrexate is an effective antifolate drug for rheumatoid arthritis, offering symptomatic relief and a favorable efficacy/toxicity ratio. While its exact mechanism is unclear, it acts as an anti-inflammatory and immunomodulating agent.
Area of Science:
- Rheumatology
- Pharmacology
- Immunology
Background:
- Methotrexate is an approved treatment for rheumatoid arthritis (RA), increasingly prescribed early in the disease course.
- Its precise mechanism in RA remains incompletely understood, despite its known antifolate properties.
Purpose of the Study:
- To elucidate the mechanism of action of methotrexate in rheumatoid arthritis.
- To evaluate the efficacy, pharmacokinetics, and toxicity profile of methotrexate for RA treatment.
Main Methods:
- Review of existing literature on methotrexate's mechanism, clinical trials, and pharmacokinetic studies.
- Analysis of data on methotrexate's effects on enzymes, cytokines, and cellular proliferation.
- Examination of bioavailability, metabolism, and excretion pathways.
Main Results:
- Methotrexate's polyglutamated derivatives inhibit key enzymes (e.g., dihydrofolate reductase) and affect cytokines (e.g., IL-1).
- The drug exhibits anti-inflammatory and immunomodulating properties, potentially inhibiting synovial cell proliferation.
- Weekly low-dose methotrexate demonstrates early symptomatic improvement and a favorable efficacy/toxicity ratio in RA patients.
Conclusions:
- Methotrexate is a highly efficacious slow-acting antirheumatic agent, comparable to parenteral gold, penicillamine, and sulfasalazine.
- While not definitively disease-modifying, methotrexate shows favorable long-term adherence compared to other slow-acting drugs.
- Toxic effects, not lack of response, are the primary reason for discontinuing methotrexate therapy.